Episode 22 – Myasthenia gravis treatment landscape: What to expect in the future

Episode 22 – Maria Da Silva Leite and Nils Erik Gilhus examine how MG treatment approaches are evolving, with a focus on antibody-defined subtypes, treatment goals, and long-term disease control. They highlight how improved disease characterization is increasingly shaping therapeutic decision-making and consider the balance between efficacy and treatment burden, as well as how emerging targeted therapies and biomarkers may enable more selective, patient-centered management in the future.